Ignite Creation Date:
2024-07-17 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06478472
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-23
Brief Title:
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab OR for Primary Marginal Zone Lymphoma MZL That Failed or Not Suitable for Local Therapy
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
The First Affiliated Hospital of Xiamen University
Study Overview
Official Title:
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab OR for Primary Marginal Zone Lymphoma MZL That Failed or Not Suitable for Local Therapy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Orelabrutinib combined with rituximab OR therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None